IP Verse

Use Of An Anti-Pd-1 Antibody In Combination With An Anti-Cd30 Antibody In Lymphoma Treatment - EP3464368

The patent EP3464368 was granted to Bristol Myers Squibb on Jun 28, 2023. The application was originally filed on Jun 1, 2017 under application number EP17730629A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3464368

BRISTOL MYERS SQUIBB
Application Number
EP17730629A
Filing Date
Jun 1, 2017
Status
Granted And Under Opposition
May 26, 2023
Grant Date
Jun 28, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANMar 25, 2024HOFFMANN EITLEADMISSIBLE

Patent Citations (22) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2013017199
DESCRIPTIONUS2014341917
DESCRIPTIONUS2014356353
DESCRIPTIONUS2015079109
DESCRIPTIONUS6808710
DESCRIPTIONUS7488802
DESCRIPTIONUS7943743
DESCRIPTIONUS8008449
DESCRIPTIONUS8168757
DESCRIPTIONUS8217149
DESCRIPTIONUS8354509
DESCRIPTIONUS8609089
DESCRIPTIONUS8779108
DESCRIPTIONUS8900587
DESCRIPTIONWO2012145493
DESCRIPTIONWO2013173223
DESCRIPTIONWO2014179664
DESCRIPTIONWO2014194302
DESCRIPTIONWO2015085847
DESCRIPTIONWO2015112800
DESCRIPTIONWO2015112900
DESCRIPTIONWO2016149201

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma", ClinicalTrials.gov ID NCT02572167, (20160527), ClinicalTrials.gov ID NCT02572167, URL: https://clinicaltrials.gov/study/NCT02572167?tab=history&a=9, XP093181229-
OPPOSITION- Anonymous, "A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma", ClinicalTrials.gov ID NCT02572167, (20160829), ClinicalTrials.gov ID NCT02572167, URL: https://clinicaltrials.gov/study/NCT02572167?tab=history&a=12, XP093181233-
OPPOSITION- Freeman Stuart, "Principles ofCancerManagement: Chemotherafy", Cancer, Principles & Practice of Oncology, 6th Edition, (20010101), page 292, XP093259101-
OPPOSITION- Merli Michele; Ferrario Andrea; Maffioli Margherita; Olivares Cecilia; Stasia Alessandra; Arcaini Luca; Passamonti Francesco, "New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.", Expert review of hematology England, Informa UK, UK, UK , (20160731), vol. 9, no. 8, doi:10.1080/17474086.2016.1205949, ISSN 1747-4094, pages 767 - 780, XP009510480
OPPOSITION- Joseph Maly; Lapo Alinari, "Pembrolizumab in classical Hodgkin's lymphoma", European journal of haematology, DK , (20160505), vol. 97, no. 3, doi:10.1111/ejh.12770, ISSN 0902-4441, pages 219 - 227, XP071760753
OPPOSITION- S. Arulogun; M. Hertzberg; M. K. Gandhi, "Recent treatment advances in Hodgkin lymphoma: a concise review", INTERNAL MEDICINE JOURNAL, BLACKWELL SCIENCE,, AU, AU , (20161215), vol. 46, no. 12, doi:10.1111/imj.13051, ISSN 1444-0903, pages 1364 - 1369, XP072168491
OPPOSITION- Herrera Alex F, Bartlett Nancy L, Ramchandren Radhakrishnan, Vose Julie M, Moskowitz Alison J, Feldman Tatyana A, Lacasce Ann S, Ansell Stephen M, Moskowitz Craig H., Fenton Keenan, Kato Kazunobu, Fong Abraham, Advani Ranjana H, "Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma", Blood, American Society of Hematology, US, US , (20161202), vol. 128, no. 22, doi:10.1182/blood.V128.22.1105.1105, ISSN 0006-4971, page 1105, XP093181219
OPPOSITION- Bond David, Alinari Lapo, "Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab", Journal of blood medicine, Taylor & Francis Ltd, New Zealand, New Zealand , (20170511), vol. 8, doi:10.2147/JBM.S117452, ISSN 1179-2736, pages 41 - 54, XP093179511

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents